NCT03505515 is a clinical trial in Lung Cancer, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT03505515?

NCT03505515 is sponsored by Bristol-Myers Squibb.

What condition does NCT03505515 study?

NCT03505515 studies Lung Cancer, Non-small Cell Lung Cancer NSCLC, Small Cell Lung Cancer SCLC.

Is NCT03505515 still recruiting?

NCT03505515 is currently completed. Last updated 14 September 2021.

Last reviewed 2021-09-14 · How we verify

NCT03505515

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer

Completed Last updated 14 September 2021

What this trial tests

trial in Lung Cancer in 6,205 participants. Completed in 11 September 2020.

Timeline

7 December 2017

Primary endpoint
11 September 2020

11 September 2020

Quick facts

Lead sponsor	Bristol-Myers Squibb
Status	Completed
Study type	OBSERVATIONAL
Enrollment	6,205
Start date	7 December 2017
Primary completion	11 September 2020
Estimated completion	11 September 2020
Sites	1 location across China

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Non-small Cell Lung Cancer NSCLC — all drugs for Non-small Cell Lung Cancer NSCLC →
Small Cell Lung Cancer SCLC — all drugs for Small Cell Lung Cancer SCLC →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

18 and older, any sex, with Lung Cancer or Non-small Cell Lung Cancer NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to document real-world pattern of care, outcomes and health resource use for participants diagnosed with and receiving treatment for advanced Non-small cell lung cancer (NSCLC) and extensive disease Small cell lung cancer (SCLC) in China.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Treatment patterns, clinical outcomes, and healthcare resource use associated with advanced/metastatic lung cancer in China: protocol for a retrospective observational study.
Qiu B, Li G, Luo F, Cai X, et al · · 2020 · cited 1× · PMID 33489806 · DOI 10.21037/tlcr-20-1269

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03505515 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 14 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03505515.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing